Tiagabine Hydrochloride Tablet, Film Coated
Product Images NDC 62756-224

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tiagabine Hydrochloride (NDC 62756-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
The text is a chemical formula for the compound C7H7N, where seven carbon atoms, seven hydrogen atoms, and one nitrogen atom are arranged in a specific order.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
This is a chart showing the percentage reduction in partial seizure rate of patients taking Tiagabine Hydrochloride 32 + 56 mg/day compared to the placebo. The chart also displays the percentage of patients who experienced improvement or worsening.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
This appears to be a visual representation of the reduction in partial seizure rate for different dosages (16 mg/day, 32 mg/day, and 56 mg/day) of Tiagabine Hydrochloride. The chart shows that increasing the dosage of Tiagabine Hydrochloride results in a greater reduction in partial seizure rate. The chart also includes a percentage of patients who experience either improvement or worsening of their condition with each dosage.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
This appears to be a graph showing the reduction in partial seizure rate for patients taking a placebo versus patients taking Tiagabine Hydrochloride 10 mg TID. The graph shows a range from -150% to 100%, with the percentage of patients on the y-axis ranging from 0% to 100%. The x-axis includes the categories of Placebo and Tiagabine Hydrochloride and displays the range of -100% to 100% in increments of 50%. The graph also includes a line indicating the point at which there is no change in the rate of seizures.*
FDA Label Image

Tiagabin-label-2mg (Tiagabine Label 2mg)

Tiagabin-label-2mg (Tiagabine Label 2mg)
This is a medication called Tiagabine Hydrochloride Tablet, which comes in a package containing 30 tablets. Each tablet contains 2mg of Tiagabine Hycrochloride, USP, and it is recommended to refer to the package insert for the complete prescribing information. The tablets should be dispensed in a USP light-resistant container and must be protected from light and moisture. The medication guide needs to be given to each patient along with the prescription, and the tablets need to be stored at room temperature. This medication is available only on prescription and is distributed by Sun Pharmaceutical Industries Inc. in Cranbury, NJ. Manufacturing is done by Sun Pharmaceutical Ind. Ltd. in Halol-Baroda Highway, Halol-389 350, Gujarat, India.*
FDA Label Image

Tiagabine-label-4mg (Tiagabine Label 4mg)

Tiagabine-label-4mg (Tiagabine Label 4mg)
This is a medication called tiagabine hydrochloride, USP that comes in coated tablets of 4mg each. The package insert contains prescribing information, and it should not be used if the seal is broken or missing. The tablets should be dispensed in a light-resistant container and stored between 20-25°C to protect them from light and moisture. It is distributed by Sun Pharmaceuticals Industries, Inc. and manufactured by Sun Pharmaceutical Ind. Lid. in Halol-Baroda Highway, Halol-389 350, Gujaral, India. Information for pharmacists is also provided.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.